Oméga-3 fortement dosés pour la prévention cardiovasculaire : une fausse bonne idée ? [High-dose Omega-3 for cardiovascular prevention, a bad idea?]
Fiche du document
9 mars 2022
- doi: 10.53738/REVMED.2022.18.772.434
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.772.434
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35266343
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7636797E28753
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
LDL (Lipoproteins) Beta lipoproteins Lipoproteins, LDL Bêta-Lipoprotéines LDL Patientes Prévention et mesures de lutte Programmes de préventionCiter ce document
Christine Berger et al., « Oméga-3 fortement dosés pour la prévention cardiovasculaire : une fausse bonne idée ? [High-dose Omega-3 for cardiovascular prevention, a bad idea?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.772.434
Métriques
Partage / Export
Résumé
Hypertriglyceridemia is a cardiovascular risk factor independent of LDL cholesterol. Omega-3 reduce triglycerides levels, but without proven benefit to reduce cardiovascular risk. Recently, two studies on high-dose omega-3 derivatives have shown contradictory results on the risk of cardiovascular events: REDUCE-IT (4 g/day of icosapent ethyl) showed a 25 % reduction; STRENGTH (4 g/day of a mixture of eicosapentaenoic acid and docosahexaenoic acid) showed no effect. An increased risk of atrial fibrillation was observed in both studies. The European 2021 cardiovascular prevention guidelines propose to consider high-dose ethyl icosapent on a case-by-case basis in patients with hypertriglyceridemia.